[en] AIMS: Preliminary data have suggested that metformin might potentiate cardiovascular (CV) protection by dipeptidyl peptidase-4 inhibitors (DPP-4is), but reduce CV protection by sodium-glucose cotransporter type-2 inhibitors (SGLT2is), in patients with type 2 diabetes (T2DM) at high CV-related risk. For this reason, the present meta-analyses aimed to compare metformin moderation of the CV effects of the two pharmacological classes. METHODS: Major adverse CV events (3-point MACEs) were counted in high-risk patients with T2DM treated with or without metformin as background therapy in five CV outcome trials with DPP-4is (SAVOR-TIMI 53, EXAMINE, TECOS, CARMELINA, CAROLINA) involving 24,821 patients (17,870 with and 6951 without metformin) and 2550 events (1696 with and 854 without metformin), and four trials with SGLT2is (EMPA-REG OUTCOME, CANVAS, DECLARE-TIMI 58, VERTIS CV) involving 24,563 patients (19,090 with and 5473 without metformin) and 1829 events (1300 with and 529 without metformin). RESULTS: DPP-4is failed to reduce 3-point MACEs in both metformin users (OR: 0.96, 95% CI: 0.89-1.03) and non-users (OR: 1.05, 95% CI: 0.95-1.16), with no heterogeneity between trials and no significant between-subgroup differences (P = 0.4074), whereas SGLT2is significantly reduced 3-point MACEs in both patients with (OR: 0.91, 95% CI: 0.84-0.98) and without (OR: 0.81, 95% CI: 0.71-0.91) metformin, but again with no heterogeneity between trials and no significant between-subgroup differences (P = 0.2977). Overall, metformin non-users had a poorer risk profile than metformin users. CONCLUSION: Our meta-analyses involving a larger number of trials than before have revealed that background metformin therapy has no significant influence on either the neutral impact of DPP-4is or the positive impact of SGLT2is on CV events (3-point MACEs) in T2DM patients at high CV risk.
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
Griffin, S.J., Leaver, J.K., Irving, G.J., Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia 60 (2017), 1620–1629.
Harrington, J.L., de Albuquerque Rocha, N., Patel, K.V., Verma, S., McGuire, D.K., Should metformin remain first-line medical therapy for patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease? An alternative approach. Curr Diabetes Rep, 18, 2018, 64.
Cosentino, F., Grant, P.J., Aboyans, V., Bailey, C.J., Ceriello, A., Delgado, V., et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41 (2020), 255–323.
Das, S.R., Everett, B.M., Birtcher, K.K., Brown, J.M., Januzzi, J.L. Jr, Kalyani, R.R., et al. Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76 (2020), 1117–1145.
Buse, J.B., Wexler, D.J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63 (2020), 221–228.
Scheen, A.J., Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes Metab 46 (2020), 181–185.
Petrie, J.R., Rossing, P.R., Campbell, I.W., Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab 22 (2020), 904–915.
Inzucchi, S.E., Fitchett, D., Jurisic-Erzen, D., Woo, V., Hantel, S., Janista, C., et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. Diabetes Obes Metab 22 (2020), 631–639.
Scheen, A.J., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Crowley, M.J., Williams, J.W. Jr, Kosinski, A.S., D'Alessio, D.A., Buse, J.B., Metformin use may moderate the effect of DPP-4 Inhibitors on cardiovascular outcomes. Diabetes Care 40 (2017), 1787–1789.
Scheen, A.J., Metformin - A cardiovascular moderator of DPP-4 inhibitors?. Nature Rev Endocrinol 14 (2018), 8–9.
Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369 (2013), 1327–1335.
Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
Rosenstock, J., Perkovic, V., Johansen, O.E., Cooper, M.E., Kahn, S.E., Marx, N., et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321 (2018), 69–79.
Rosenstock, J., Kahn, S.E., Johansen, O.E., Zinman, B., Espeland, M.A., Woerle, H.J., et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322 (2019), 1155–1166.
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Neal, B., Perkovic, V., Mahaffey, K.W., de Zeeuw, D., Fulcher, G., Erondu, N., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377 (2017), 644–657.
Wiviott, S.D., Raz, I., Bonaca, M.P., Mosenzon, O., Kato, E.T., Cahn, A., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380 (2019), 347–357.
Cannon, C.P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383 (2020), 1425–1435.
Cahn, A., Wiviott, S.D., Mosenzon, O., Murphy, S.A., Goodrich, E.L., Yanuv, I., et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58. Diabetes Obes Metab, 2020, 10.1111/dom.14179 Epub:Aug 26.
Crowley, M.J., Gokhale, M., Pate, V., Sturmer, T., Buse, J.B., Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: an analysis of medicare claims data from 2007 to 2015. Diabetes Obes Metab 21 (2019), 854–865.
Bergmark, B.A., Bhatt, D.L., McGuire, D.K., Cahn, A., Mosenzon, O., Steg, P.G., et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 trial. Circulation 140 (2019), 1004–1014.
Crowley, M.J., McGuire, D.K., Alexopoulos, A.S., Jensen, T.J., Rasmussen, S., Saevereid, H.A., et al. Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: post hoc analyses of the LEADER trial. Diabetes Care 43 (2020), e108–e110.
Kristensen, S.L., Rorth, R., Jhund, P.S., Docherty, K.F., Sattar, N., Preiss, D., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
Pantalone, K.M., Munir, K., Hasenour, C.M., Atisso, C.M., Varnado, O.J., Maldonado, J.M., et al. Cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists: a comparison of study designs, populations and results. Diabetes Obes Metab, 2020, 10.1111/dom.14165 Epub:Aug 3.
Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Bonaca, M.P., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes: comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Zelniker, T.A., Wiviott, S.D., Raz, I., Im, K., Goodrich, E.L., Furtado, R.H.M., et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation 139 (2019), 2022–2031.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
Ioannidis, J.P., The proposal to lower P value thresholds to 0.005. JAMA 319 (2018), 1429–1430.
Monnier, L., Bonnet, F., Statistical and clinical significance: Are they equivalent?. Diabetes Metab 46 (2020), 413–414.
Monnier, L., Colette, C., Bonnet, F., Owens, D., Number Needed-to-Treat (NNT): is it a necessary marker of therapeutic efficiency?. Diabetes Metab 46 (2020), 261–264.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
